India Proposes Expanding Import Gateways for Drugs, Medical Devices and Cosmetics to Strengthen Healthcare Infrastructure
The Government of India has proposed expanding the country's authorised import gateways for drugs, medical devices and cosmetics to improve logistics efficiency and strengthen the healthcare supply chain. The Ministry of Health and Family Welfare has introduced a draft amendment to Rule 43A of the Drugs Rules, 1945, proposing the addition of ten new import locations across Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka.
The proposal includes eight Inland Container Depots (ICDs), the Bommasandra Special Economic Zone in Karnataka and Noida International Airport in Uttar Pradesh. The expansion aims to make the import process more accessible for pharmaceutical companies, medical equipment manufacturers and distributors by bringing authorised entry points closer to major industrial and commercial centres. The initiative is expected to improve transportation connectivity, reduce logistical challenges and support the smoother movement of imported healthcare products across different regions.
New Import Locations to Improve Accessibility
The proposed expansion includes Inland Container Depots at Sonipat, Piyala and Garhi Harsaru in Haryana; Dadri in Uttar Pradesh; Gandhidham/Mundra in Gujarat; Sanath Nagar and Thimmapur in Hyderabad, Telangana; and Whitefield in Bengaluru, Karnataka. The Bommasandra Special Economic Zone and Noida International Airport have also been included in the proposal.
These facilities will supplement India's existing authorised import network and provide businesses with additional options for bringing healthcare products into the country. The inclusion of Noida International Airport is particularly relevant for pharmaceutical imports transported by air, offering another potential entry point for consignments that require efficient transportation. By expanding the network, the government aims to improve access to import facilities and reduce the dependence on a limited number of entry points.
Strengthening India's Pharmaceutical and Medical Device Sectors
India has established itself as an important pharmaceutical manufacturing and export hub, with a growing presence in the global healthcare industry. The country's pharmaceutical and medical technology sectors also depend on international supply chains for specialised equipment, medical components, advanced technologies and certain pharmaceutical inputs.
Efficient import infrastructure is therefore essential for maintaining the availability of these products and supporting industrial operations. Additional authorised entry points could help businesses reduce transportation distances, manage inventory more effectively and improve the movement of imported consignments.
The proposed changes are also expected to benefit medical technology companies by making customs clearance more convenient. Industry representatives have highlighted that improved access to clearance facilities can help reduce logistics costs and delays, ultimately supporting the timely availability of medical technologies for healthcare providers.
Noida International Airport to Support Pharmaceutical Imports
The proposed inclusion of Noida International Airport as an authorised entry point for drug imports is another significant development. The airport is expected to strengthen air connectivity and logistics infrastructure in the National Capital Region.
Its addition could provide pharmaceutical importers with another option for transporting medicines and other healthcare-related products. Efficient air cargo connectivity is particularly important for products that require specialised handling, controlled storage conditions or faster transportation. The development could also encourage the growth of logistics and distribution facilities around the airport, strengthening the region's role in India's wider healthcare supply chain.
Improving Ease of Doing Business and Supply Chain Efficiency
The proposed amendment to Rule 43A reflects the importance of developing a more accessible and efficient import framework. Businesses operating in different parts of India often face additional transportation requirements when imported consignments enter through distant locations. Expanding authorised gateways could help address these challenges by bringing clearance facilities closer to industrial hubs.
The initiative also complements India's broader efforts to strengthen domestic pharmaceutical manufacturing and medical device production. While expanding local manufacturing capabilities remains important, access to international technologies, specialised equipment and essential inputs continues to support the development of the healthcare sector.
Importantly, the proposed expansion concerns the availability of authorised entry points and does not remove existing regulatory requirements for the quality, safety and approval of imported products.
Stakeholder Consultation Before Final Implementation
The Ministry of Health and Family Welfare has invited objections and suggestions from stakeholders regarding the draft amendment. Pharmaceutical companies, medical device manufacturers, importers and industry associations can submit their feedback to the ministry within the prescribed consultation period.
The suggestions will be considered before the proposed changes are finalised. This consultation process provides an opportunity for industry participants to share their practical requirements and contribute to the development of a more efficient import framework.
The MGMM Outlook
India’s proposal to expand authorised import gateways for drugs, medical devices and cosmetics marks an important step towards strengthening the country’s healthcare infrastructure and supply-chain efficiency. The addition of ten new locations, including Inland Container Depots, Bommasandra Special Economic Zone and Noida International Airport, is expected to improve import accessibility, reduce transportation challenges and support the smoother movement of essential healthcare products. The initiative also reflects the government’s focus on improving ease of doing business while supporting India’s growing pharmaceutical and medical technology industries.
As India continues to strengthen its position as a global pharmaceutical and healthcare manufacturing hub, efficient logistics and reliable access to advanced medical technologies remain essential. Expanding authorised import facilities can help businesses manage costs, improve distribution and ensure better availability of specialised medicines, equipment and medical components. With stakeholder consultations underway, the proposed changes represent a forward-looking effort to modernise healthcare logistics while maintaining existing quality and safety regulations.
Comments